Live Analyst Rating Changes 11232 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Ha
BAIRD
Michael Ha
Robert W. Baird
Wall Street Analyst
★★★★★
#190
on 13Foresight · ranked by our own returns
79%
Success Rate
+16.5%
Average Return
15 of 19 calls profitable · +11.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 79% of Michael Ha's ratings turned a profit when each position was held for 2 year — averaging +16.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

13 Buy 24 Hold 3 Sell
Michael's Stock Coverage 16 ratings · 2026-07-21
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
UNH
UnitedHealth
 Jul 17, 2026 HOLD Strong Buy
+5.4% avg upside
36 analysts
$453.00
7.38% Upside
 +2.4% ·
ELV
Elevance Health
 Jul 16, 2026 HOLD Strong Buy
+17.9% avg upside
33 analysts
$393.00
2.83% Upside
 +5.5% ·
MIG
VanEck Moody's Analytics IG Corporate Bond ETF
 Jun 05, 2026 BUY Strong Buy
10 analysts
 — +0.0% ·
MOH
Molina Healthcare
 May 11, 2026 HOLD Hold
+3.0% avg upside
26 analysts
$163.00
29.12% Downside
 +22.3% ·
ASTH
Astrana Health
 May 08, 2026 BUY Strong Buy
+26.3% avg upside
16 analysts
$45.00
1.08% Upside
 +14.8% ·
OSCR
Oscar Health
 May 07, 2026 HOLD Buy
-37.0% avg upside
15 analysts
$19.00
35.85% Downside
 +39.4% ·
AGL
Agilon Health
 May 07, 2026 HOLD Buy
-59.6% avg upside
26 analysts
$35.00
71.34% Downside
 +104.9% ·
THC
Tenet Healthcare
 May 05, 2026 HOLD Strong Buy
+9.4% avg upside
26 analysts
$210.00
8.03% Upside
 +5.0% ·
CI
Cigna
 May 01, 2026 BUY Strong Buy
+21.3% avg upside
29 analysts
$337.00
18.76% Upside
 +0.1% ·
CNC
Centene
 Apr 30, 2026 HOLD Buy
+6.8% avg upside
29 analysts
$46.00
30.08% Downside
 +25.9% ·
UHS
Universal Health
 Apr 29, 2026 HOLD Buy
+36.0% avg upside
22 analysts
$204.00
35.50% Upside
 -8.5% ·
CVS
CVS Health
 Apr 15, 2026 BUY Strong Buy
-3.6% avg upside
39 analysts
$94.00
12.61% Downside
 +48.8% ·
ALHC
Alignment Healthcare
 Jan 30, 2026 BUY Strong Buy
+4.8% avg upside
19 analysts
$28.00
32.61% Upside
 -6.3% ·
HUM
Humana
 Aug 14, 2025 HOLD Buy
-11.6% avg upside
34 analysts
 — +39.4% ·
PRVA
Privia Health Group
 Aug 14, 2025 BUY Strong Buy
+20.5% avg upside
26 analysts
$27.00
2.82% Upside
 +35.7% ·
HCA
HCA Healthcare
 Aug 14, 2025 HOLD Buy
+10.3% avg upside
36 analysts
$423.00
14.13% Upside
 -4.6% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Ha — Frequently Asked Questions
How accurate are Michael Ha's stock ratings?
Based on the calls 13Foresight could measure, about 79% of Michael's ratings were profitable over a one-year hold, with an average return of +16.3% per rating, or +11.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Michael ranked on 13Foresight?
Michael Ha is currently ranked #190 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on UNH, ELV, MIG, MOH, ASTH, OSCR, AGL, THC, CI, CNC, UHS, CVS and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.